Cidara Historical Income Statement

CDTX Stock

USD 21.58 0.75 3.60%

Historical analysis of Cidara Therapeutics income statement accounts such as Selling General Administrative of 14.7 M, Other Operating Expenses of 186.2 M or Research Development of 51.5 M can show how well Cidara Therapeutics performed in making a profits. Evaluating Cidara Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cidara Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cidara Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cidara Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

About Cidara Income Statement Analysis

Cidara Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cidara Therapeutics shareholders. The income statement also shows Cidara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cidara Therapeutics Income Statement Chart

At this time, Cidara Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 6.1 M in 2025, whereas Interest Expense is likely to drop slightly above 210.4 K in 2025.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cidara Therapeutics. It is also known as Cidara Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Cidara Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 6.1 M in 2025, whereas Interest Expense is likely to drop slightly above 210.4 K in 2025.

Cidara Therapeutics income statement Correlations

	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Depreciation And Amortization	Gross Profit	Net Income From Continuing Ops	Non Recurring	Income Tax Expense	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation	Interest Income
Interest Expense		0.64	0.47	-0.43	-0.72	0.61	-0.44	0.61	-0.42	0.51	-0.42	0.05	-0.23	-0.38	-0.12	0.25	0.17	0.73	-0.22	0.12
Selling General Administrative	0.64		0.81	-0.62	-0.67	0.98	-0.63	0.99	-0.62	0.49	-0.63	-0.07	-0.07	-0.57	-0.27	-0.36	0.36	0.07	-0.41	0.33
Other Operating Expenses	0.47	0.81		-0.91	-0.34	0.81	-0.91	0.81	-0.91	0.81	-0.91	-0.07	-0.38	-0.9	-0.77	-0.23	0.8	-0.04	-0.37	0.78
Operating Income	-0.43	-0.62	-0.91		0.32	-0.58	1.0	-0.59	1.0	-0.86	1.0	0.01	0.7	1.0	0.84	0.18	-0.85	-0.03	0.25	-0.86
Ebit	-0.72	-0.67	-0.34	0.32		-0.65	0.33	-0.65	0.33	-0.13	0.33	-0.09	0.25	0.27	-0.1	0.19	0.16	-0.35	0.22	0.16
Research Development	0.61	0.98	0.81	-0.58	-0.65		-0.58	1.0	-0.58	0.45	-0.59	-0.07	-0.01	-0.54	-0.25	-0.27	0.32	0.03	-0.43	0.3
Ebitda	-0.44	-0.63	-0.91	1.0	0.33	-0.58		-0.59	1.0	-0.87	1.0	0.02	0.7	1.0	0.84	0.16	-0.85	-0.05	0.26	-0.86
Total Operating Expenses	0.61	0.99	0.81	-0.59	-0.65	1.0	-0.59		-0.59	0.46	-0.6	-0.07	-0.02	-0.55	-0.26	-0.29	0.33	0.04	-0.43	0.3
Income Before Tax	-0.42	-0.62	-0.91	1.0	0.33	-0.58	1.0	-0.59		-0.85	1.0	0.01	0.7	1.0	0.84	0.19	-0.85	-0.01	0.25	-0.85
Total Other Income Expense Net	0.51	0.49	0.81	-0.86	-0.13	0.45	-0.87	0.46	-0.85		-0.85	0.02	-0.56	-0.86	-0.82	0.1	0.9	0.3	-0.16	0.88
Net Income	-0.42	-0.63	-0.91	1.0	0.33	-0.59	1.0	-0.6	1.0	-0.85		0.02	0.69	1.0	0.84	0.19	-0.84	-0.01	0.26	-0.85
Depreciation And Amortization	0.05	-0.07	-0.07	0.01	-0.09	-0.07	0.02	-0.07	0.01	0.02	0.02		-0.07	0.02	0.04	-0.11	-0.02	0.11	0.87	-0.05
Gross Profit	-0.23	-0.07	-0.38	0.7	0.25	-0.01	0.7	-0.02	0.7	-0.56	0.69	-0.07		0.72	0.58	-0.02	-0.52	-0.19	-0.06	-0.56
Net Income From Continuing Ops	-0.38	-0.57	-0.9	1.0	0.27	-0.54	1.0	-0.55	1.0	-0.86	1.0	0.02	0.72		0.86	0.16	-0.86	0.0	0.24	-0.87
Non Recurring	-0.12	-0.27	-0.77	0.84	-0.1	-0.25	0.84	-0.26	0.84	-0.82	0.84	0.04	0.58	0.86		0.07	-0.92	0.11	0.15	-0.93
Income Tax Expense	0.25	-0.36	-0.23	0.18	0.19	-0.27	0.16	-0.29	0.19	0.1	0.19	-0.11	-0.02	0.16	0.07		-0.05	0.67	-0.06	-0.09
Net Interest Income	0.17	0.36	0.8	-0.85	0.16	0.32	-0.85	0.33	-0.85	0.9	-0.84	-0.02	-0.52	-0.86	-0.92	-0.05		-0.06	-0.14	1.0
Non Operating Income Net Other	0.73	0.07	-0.04	-0.03	-0.35	0.03	-0.05	0.04	-0.01	0.3	-0.01	0.11	-0.19	0.0	0.11	0.67	-0.06		0.06	-0.1
Reconciled Depreciation	-0.22	-0.41	-0.37	0.25	0.22	-0.43	0.26	-0.43	0.25	-0.16	0.26	0.87	-0.06	0.24	0.15	-0.06	-0.14	0.06		-0.16
Interest Income	0.12	0.33	0.78	-0.86	0.16	0.3	-0.86	0.3	-0.85	0.88	-0.85	-0.05	-0.56	-0.87	-0.93	-0.09	1.0	-0.1	-0.16

Click cells to compare fundamentals

Cidara Therapeutics Account Relationship Matchups

Cidara Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	221K	262K	212K	191K	219.7K	210.4K
Selling General Administrative	15.9M	18.7M	18.5M	18.3M	20.6M	14.7M
Other Operating Expenses	83.9M	91.8M	94.0M	88.4M	177.4M	186.2M
Operating Income	(71.8M)	(42.3M)	(29.7M)	(24.5M)	(176.1M)	(167.3M)
Ebit	(71.8M)	(42.3M)	(29.7M)	(24.5M)	(22.0M)	(23.1M)
Research Development	68.0M	73.1M	75.5M	68.5M	71.9M	51.5M
Ebitda	(71.6M)	(43.5M)	(28.5M)	(24.4M)	(176.1M)	(167.3M)
Total Operating Expenses	83.9M	91.8M	94.0M	86.9M	92.5M	66.2M
Income Before Tax	(72.1M)	(42.5M)	(29.5M)	(22.5M)	(170.3M)	(161.8M)
Total Other Income Expense Net	(262K)	(212K)	191K	2.0M	5.8M	6.1M
Net Income	(72.4M)	(43.9M)	(29.8M)	(22.9M)	(169.8M)	(161.3M)
Depreciation And Amortization	286K	(1.2M)	1.2M	118K	106.2K	204K
Total Revenue	12.1M	49.6M	64.3M	63.9M	1.3M	1.2M
Gross Profit	(56.0M)	49.6M	64.3M	62.4M	(83.6M)	(79.4M)
Net Income From Continuing Ops	(72.1M)	(42.5M)	(29.8M)	(22.9M)	(170.3M)	(161.8M)
Cost Of Revenue	68.0M	189K	143K	1.5M	84.9M	89.1M
Net Income Applicable To Common Shares	(41.1M)	(74.9M)	(42.5M)	(29.8M)	(26.8M)	(28.2M)
Income Tax Expense	262K	1.4M	272K	443K	509.5K	606.8K
Net Interest Income	(262K)	(212K)	191K	2.0M	5.8M	6.1M
Non Operating Income Net Other	4.3M	632K	(262K)	191K	171.9K	163.3K
Reconciled Depreciation	286K	(1.2M)	1.2M	118K	233K	215K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cidara Historical Income Statement

About Cidara Income Statement Analysis

Cidara Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Cidara Therapeutics income statement Correlations

Cidara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cidara Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Cidara Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Net Income From Continuing Ops	+ 1.0	Operating Income
Total Operating Expenses	+ 1.0	Research Development
Income Before Tax	+ 1.0	Ebitda

Interest Income	- 0.93	Non Recurring
Net Interest Income	- 0.92	Non Recurring
Net Income	- 0.91	Other Operating Expenses
Income Before Tax	- 0.91	Other Operating Expenses
Ebitda	- 0.91	Other Operating Expenses
Operating Income	- 0.91	Other Operating Expenses